Nelson M. Sims joins Aastrom Biosciences' Board of Directors
Advertisement
Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Nelson M. Sims has been elected to the Company's Board of Directors. He will serve as a Class III Director whose initial term expires at the 2006 Annual Meeting of Shareholders.
Mr. Sims joins Aastrom's Board with over 30 years of pharmaceutical industry experience. Most recently Mr. Sims was the President and Chief Executive Officer of Novavax, Inc., an international health and life science company. Prior to this, Mr. Sims held several senior executive management positions with Eli Lilly and Company until his retirement in 2001. During his 28 year tenure at Eli Lilly, Mr. Sims' positions included President of Eli Lilly Canada, Inc., Executive Director of Alliance Management, Vice President of Hybritech, Inc. and other assignments in sales and marketing management and business development. In his last position with Eli Lilly, Mr. Sims lead the Alliance Management initiative responsible for "Best in Class" partnering capabilities for research and development, commercial and development alliances.
Mr. Sims received a Bachelor of Science degree in Pharmacy at Southwestern Oklahoma State University, and completed the Tuck Executive Program at the Amos Tuck School of Business at Dartmouth College. He also serves on the board of MDS, Inc.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Oncolytics Biotech Inc. Appoints Senior Vice President, Global Licensing and Business Development
EKF Diagnostics acquires Selah Genomics and DiaSpect Medical AB
Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect
Kiel Möbius Prize goes to renowned American microbiome researcher
Innovative Roche cancer medicine Avastin approved in EU - First Treatment of its Kind With Proven Survival Benefit for Patients With Advanced Colorectal Cancer
